SynopsisIndian pharma companies have been struggling to maintain margins because of strong headwinds. Due to increased competition, pharma companies are experiencing price erosion in the market, resulting in sluggish growth. While price erosion is not the only issue at hand, China’s lockdown that caused supply chain disruption, the rise in raw material prices, and the Russia-Ukraine war have raised packaging costs.Years of getting premium valuations, pharma companies’ stocks are facing reality checks. Divi’s Laboratories was able to manage the business challenges. But will valuation headwinds finally hit the stock now or will its business model be able to deliver growth that will help the stock maintain its premium?Indian pharma companies have been struggling to maintain margins because of strong headwinds. Due to increased competition, pharma companies BYGaurav Jain & Parimal AdeET CONTRIBUTORS Jul 28, 2022, 11:40 AM ISTGift A StoryShare member-only stories with your friends or family and help them read it for free.Gifting Limit Reached!Hey , no more stories left for you to gift.No worries! You will get a limit of 15 stories next month to share with your friends and family.
Gift This Story Stories Left!You can gift upto 15 stories in a month.
- FONT SIZEAbcSmallAbcMediumAbcLarge
Continue reading with one of these options:Limited AccessFreeLogin to get access to some exclusive stories
& personalised newslettersLogin NowUnlimited AccessStarting @ Rs120/monthGet access to exclusive stories, expert opinions &
in-depth stock reportsSubscribe Now
Get Unlimited Access to The Economic Times
₹34 per week
Billed annually at
₹2499 ₹1749ContinueAlready a Member? Sign In nowAlready a Member? Sign In nowSign in to read the full articleYou’ve got this Prime Story as a Free GiftRs 49 for 1st monthThen Rs. 1,749 per yearSUBSCRIBE NOWValid only with UPI, Credit & Debit Cards Autopay–
–Subscribe Now(Credit card mandatory)You can cancel your subscription anytime—Subscribe Now(Pay Using Netbanking/UPI/Debit Card)Netbanking, Credit & Debit CardSubscribe with Google₹399/monthMonthly
PLAN
Billed Amount ₹399₹399₹208/month(Save 49%)Yearly
PLAN
Billed Amount ₹2,49915
Days Trial
+Includes DocuBay and TimesPrime Membership.₹399₹150/month(Save 63%)2-Year
PLAN
Billed Amount ₹3,59915
Days Trial
+Includes DocuBay and TimesPrime Membership.Subscribe NowSubscribe with 
Exclusive Economic Times Stories, Editorials & Expert opinion across 20+ sectors- Stock analysis. Market Research. Industry Trends on 4000+ Stocks
- Clean experience with
Minimal Ads - Comment & Engage with ET Prime community
- Exclusive invites to Virtual Events with Industry Leaders
- A trusted team of Journalists & Analysts who can best filter signal from noise
.
